STOCK TITAN

If You Invested in PLUS THERAPEUTICS, Inc. (PSTV)

Healthcare · Biotechnology · NASDAQ
See the PSTV overview
PSTV has not traded since Jul 31, 2026. Its last close was $3.87, so every figure on this page ends there and the 1, 5 and 10 year results count back from that close.
$1,000 invested 1 Year Before Its Last Close
N/A
Comparable prices start Apr 2, 2026
$1,000 invested 5 Years Before Its Last Close
N/A
Comparable prices start Apr 2, 2026
$1,000 invested 10 Years Before Its Last Close
N/A
Comparable prices start Apr 2, 2026

What $1,000 or $10,000 in PSTV Was Worth at Its Last Close

Real historical value by amount invested and how long before the last close
If you invested 1 year before 5 years before 10 years before Since Apr 2, 2026
$1,000 — — — $1,087 +9%
$10,000 — — — $10,871 +9%

Based on real historical closing prices adjusted for stock splits, without dividends, through the latest market close. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results. We start PSTV on Apr 2, 2026 because the prices we hold from before that date cannot be compared with the later ones, and a return measured across the two would be wrong.

Custom Calculation

Choose your own date and amount for PSTV

$1,000 Investment Over Time

PSTV vs S&P 500

Year-by-Year Returns

PSTV annual performance
Year Start Price End Price Annual Return Cumulative
2026Apr 2 to Jul 31 $3.56 $3.87 +8.7% +8.7%

About PLUS THERAPEUTICS, Inc.

Healthcare · NASDAQ

Plus Therapeutics, Inc. (NASDAQ: PSTV) is a clinical-stage pharmaceutical company focused on targeted radiotherapeutics and precision diagnostics for difficult-to-treat cancers of the central nervous system (CNS). Headquartered in Houston, Texas, the company develops radioactive drug formulations and related technologies intended to deliver high-dose, localized radiation to CNS tumors, as well as diagnostic tools that help clinicians detect and manage CNS metastases.

Core Focus: Targeted Radiotherapeutics for CNS Cancers

According to Plus Therapeutics, its primary therapeutic programs center on REYOBIQ™ (rhenium Re186 obisbemeda), a novel injectable radiotherapy designed for CNS tumors. REYOBIQ is being evaluated in clinical trials for recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers. The company describes REYOBIQ as formulated to deliver direct, targeted high-dose radiation within CNS tumors with the goal of optimizing patient outcomes and reducing off-target exposure compared with existing therapies.

Plus Therapeutics reports that REYOBIQ is studied in the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health, while ReSPECT-LM is funded by a multi-year grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The ReSPECT-PBC trial for pediatric brain cancer is supported by a grant from the U.S. Department of Defense’s Peer Reviewed Cancer Research Program. These external grants underscore that the programs are part of broader, publicly supported research initiatives.

Technology and Development Approach

Company disclosures state that Plus Therapeutics is developing targeted radiotherapeutics with advanced platform technologies for CNS cancers. Its work with rhenium-based isotopes, including rhenium-186, is intended to exploit characteristics such as beta energy for tumor cell destruction and gamma energy for real-time imaging. The company describes its approach as combining image-guided local beta radiation with targeted drug delivery methods to concentrate radiation in tumor tissue while limiting systemic exposure.

In regulatory and investor materials, Plus Therapeutics characterizes itself as a U.S. pharmaceutical company whose formulations are designed to achieve elevated patient-absorbed radiation doses and extended retention times within tumors. The aim, as described by the company, is to allow radioactive decay to occur largely within the tumor, which may contribute to lower exposure of normal tissues and potentially improved safety margins.

Diagnostic Subsidiary: CNSide Diagnostics, LLC

Plus Therapeutics owns CNSide Diagnostics, LLC, a wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests (LDTs) for CNS cancers. CNSide Diagnostics focuses on identifying tumor cells that have metastasized to the CNS in patients with carcinomas and melanomas.

The subsidiary’s flagship offering is the CNSide® Cerebrospinal Fluid (CSF) Assay Platform, including a CSF Tumor Cell Enumeration (TCE) test. Company communications state that CNSide enables quantitative analysis of cerebrospinal fluid to support rapid diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. Plus Therapeutics reports that CNSide has demonstrated high sensitivity and specificity in clinical and real-world settings and has been used at numerous U.S. cancer institutions.

CNSide Diagnostics operates a CLIA-certified laboratory facility in Houston, Texas and provides CNSide testing as a service to U.S. health care professionals. The company notes that state licensure and payor agreements are important components of its market access and launch strategy for the CNSide platform.

Regulatory and Clinical Interactions

Plus Therapeutics frequently reports on its regulatory interactions with the U.S. Food and Drug Administration (FDA) related to REYOBIQ. The company has described Type B meetings with the FDA to discuss pivotal trial strategies for leptomeningeal metastases, including trial design, endpoints such as overall survival, and potential use of circulating tumor cells as secondary endpoints.

In public statements, Plus Therapeutics has also highlighted that REYOBIQ has been granted Fast Track and Orphan Drug designations for certain CNS cancer indications. The company indicates that these designations, along with ongoing dialogue with the FDA, inform its planning for dose optimization and potential pivotal or registrational trials.

Capital Markets and Nasdaq Listing

Plus Therapeutics’ common stock trades on the Nasdaq Capital Market under the ticker symbol PSTV. The company has disclosed multiple capital-raising activities, including a purchase agreement with Lincoln Park Capital Fund, LLC for the potential sale of up to a specified dollar amount of common stock, and an underwritten public offering of units consisting of common stock and warrants.

SEC filings and company press releases note that Plus Therapeutics has received notices from Nasdaq regarding compliance with listing standards, such as the minimum bid price requirement and stockholders’ equity thresholds. The company has reported extensions to regain compliance and has indicated that it may consider actions such as a reverse stock split if needed to meet Nasdaq’s minimum bid price rule. These disclosures provide context for investors monitoring PSTV’s listing status.

Supply Chain and Strategic Partnerships

In its public communications, Plus Therapeutics states that it has built a supply chain through strategic partnerships that support the development, manufacturing, and potential future commercialization of its radiotherapeutic products. While specific counterparties are not detailed in the provided materials, the company emphasizes that these relationships are intended to enable production and distribution of its investigational therapies and diagnostic services.

Business Structure and Sector Classification

Plus Therapeutics is incorporated in Delaware and is categorized under manufacturing-related industry codes in regulatory filings, reflecting its focus on pharmaceutical development and related technologies. However, its own descriptions consistently refer to the business as a clinical-stage pharmaceutical company and a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for CNS cancers.

The company’s activities span:

  • Development of CNS-focused radiotherapeutic drug candidates such as REYOBIQ.
  • Clinical trials in indications including leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers.
  • Operation of CNSide Diagnostics, which provides CNS-focused CSF assay testing services.
  • Engagement with regulators, grant-making institutions, and payors to support clinical development and diagnostic adoption.

Investment and Research Considerations

Investors researching PSTV stock typically review Plus Therapeutics’ SEC filings, including Forms 10-K, 10-Q, 8-K, S-1, and proxy statements, along with its clinical trial updates and grant-supported research disclosures. These documents outline the company’s risk factors, capital structure, clinical development plans, and Nasdaq listing considerations.

Because Plus Therapeutics is a clinical-stage company, its future prospects depend on the outcomes of ongoing and planned clinical trials, regulatory decisions, and the adoption of its diagnostic services. Company communications often include forward-looking statements that are subject to scientific, regulatory, and financial uncertainties, as described in its cautionary language.

Last Close
$3.87
EPS (FY2025)
-$0.29
Revenue (FY2025)
$5.2M
View full PSTV overview

Frequently Asked Questions

PLUS THERAPEUTICS, Inc. investment returns

How much was $1,000 invested in PLUS THERAPEUTICS, Inc. worth at its last close?

Limited historical data is available for PSTV. The prices we can compare start on 2026-04-02.

Has PLUS THERAPEUTICS, Inc. outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare PSTV performance over available time periods.

For informational and educational purposes only, not investment advice.